High court clears way for clinical trial giving puberty blockers to children
Summary
A UK court allowed a clinical trial to study the effects of puberty blockers on children to proceed after rejecting a legal challenge. The trial, led by King’s College London, will recruit over 220 children aged 11 to 16 to better understand the benefits and risks of puberty blockers in young people with gender identity issues.Key Facts
- A high court judge rejected a legal attempt to stop a trial on puberty blockers for children.
- The trial is called the Pathways trial and is run by King’s College London (KCL).
- Over 220 children aged 11 to 16 will be enrolled starting August 1.
- Each child will be carefully assessed by specialist doctors before treatment.
- The trial aims to provide clearer evidence on the benefits and risks of puberty blockers.
- Opponents of the trial express concern about safety and ethical issues.
- The study was approved by UK health regulators, including the Health Research Authority (HRA) and Medicines and Healthcare products Regulatory Agency (MHRA).
- Puberty blockers were used before for early puberty but were banned by the NHS last year for gender identity treatment following a review citing weak evidence.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
